Results 21 to 30 of about 489 (130)

Effect of Aficamten on Cardiac Structure and Function in Obstructive Hypertrophic Cardiomyopathy:SEQUOIA-HCM CMR Substudy [PDF]

Journal of the American College of Cardiology
Background: Obstructive hypertrophic cardiomyopathy (oHCM) is characterized by left ventricular (LV) hypertrophy, LV outflow tract obstruction, and left atrial dilation, which can be associated with progressive heart failure, atrial fibrillation, and ...
, Abraham, Theodore P., Cardoso, Rhanderson N., Claggett, Brian L., Coats, Caroline J., Hegde, Sheila M., Heitner, Stephen B., Jacoby, Daniel L., Kramer, Christopher M., Kulac, Ian J., Kupfer, Stuart, Kwong, Raymond Y., Lee, Matthew M.Y., Malik, Fady I., Maron, Martin S., Masri, Ahmad, Meng, Lisa, Merkely, Bela, Michels, Michelle, Olivotto, Iacopo, Oreziak, Artur, Solomon, Scott D., Wohltman, Amy   +22 more
core   +6 more sources

Efficacy and safety of cardiac myosin inhibitors for symptomatic hypertrophic cardiomyopathy: a meta-analysis of randomized controlled trials [PDF]

Frontiers in Cardiovascular Medicine
IntroductionHypertrophic cardiomyopathy (HCM) is a common genetic heart disorder. It is characterized by left ventricular hypertrophy and impaired cardiac function, with forms categorized into obstructive (oHCM) and nonobstructive (nHCM).
Anas Abunada, Madiha Shah, Ateesh Kumar, Syeda Lamiya Mir, Dinesh Kumar, Saboor Ahmed, Muhammad Tanzeel, Vikash Kumar, Aashish Meghjiani, Muhammad Basit Ali Siddiqui, Govinda Khatri, Aneesh Rai, Fnu Deepak, Ayush Kumar   +13 more
doaj   +2 more sources

Effects of Aficamten on cardiac contractility in a feline translational model of hypertrophic cardiomyopathy

Scientific Reports, 2023
Hypertrophic cardiomyopathy (HCM) is the most prevalent inherited cardiac disease in humans and cats and lacks efficacious pharmacologic interventions in the preclinical phase of disease.
Ashley N. Sharpe, Maureen S. Oldach, Victor N. Rivas, Joanna L. Kaplan, Ashley L. Walker, Samantha L. Kovacs, Darren T. Hwee, Peadar Cremin, Bradley P. Morgan, Fady I. Malik, Samantha P. Harris, Joshua A. Stern   +11 more
doaj   +5 more sources

Hypertrophic Cardiomyopathy: Current Perspectives [PDF]

Reviews in Cardiovascular Medicine
Hypertrophic cardiomyopathy (HCM) is a multifaceted genetic disorder characterized by left ventricular hypertrophy (LVH) in the absence of alternative causes, with an estimated prevalence ranging from 1 in 200 to 1 in 500 individuals. Since HCM was first
Dhruvil Patel, Ruchika Bhargav, Aliaa Mousa, Sabahat Bokhari   +3 more
doaj   +2 more sources

Efficacy of aficamten in patients with obstructive hypertrophic cardiomyopathy and mild symptoms: results from the SEQUOIA-HCM trial. [PDF]

Eur Heart J
Background and Aims: Patients with obstructive hypertrophic cardiomyopathy (oHCM) treated with aficamten in SEQUOIA-HCM (NCT05186818) demonstrated marked improvement in symptoms and functional capacity.
Maron MS, Gimeno JR, Veselka J, Barriales-Villa R, Claggett BL, Coats CJ, Hegde SM, Januzzi JL, Kulac IJ, Masri A, Nassif ME, Spertus JA, Jacoby DL, Heitner SB, Kupfer S, Malik FI, Wohltman A, Olivotto I.   +17 more
europepmc   +3 more sources

Characterization and Application of Novel Exercise Recovery Patterns That Reflect Cardiac Performance: A Substudy of the SEQUOIA-HCM Trial. [PDF]

Circulation
BACKGROUND: Post-exercise oxygen uptake recovery (VO₂Rec) is slow in advanced heart failure. We sought to establish easily derived VO₂Rec measures and evaluate their cardiospecificity and prognostic relevance in patients with dyspnea on exertion.
Campain J, Griskowitz C, Newlands C, Claggett BL, Kulac IJ, McGinnis S, Giverts I, Moreno F, Minasian A, Prasad C, Rupert L, Landsteiner I, Iskenderian N, Coats CJ, Lee MMY, Maron MS, Owens AT, Jacoby DL, Heitner SB, Kupfer S, Malik FI, Wohltman A, Malhotra R, Lewis GD.   +23 more
europepmc   +3 more sources

Efficacy of cardiac myosin inhibitors mavacamten and aficamten in hypertrophic cardiomyopathy: a systematic review and meta-analysis of randomised controlled trials [PDF]

Open Heart
Background Unlike other suggested therapies, myosin inhibitors have been shown to change the course of hypertrophic cardiomyopathy by altering the contractile mechanics of cardiomyocytes.
Ayesha Aman, Arfa Akram, Bisma Akram, Momina Maham, Masooma Zainab Bokhari, Aleena Akram, Sania Akram, Furqan Yaqub   +7 more
doaj   +2 more sources

Integrative Approaches in the Management of Hypertrophic Cardiomyopathy: A Comprehensive Review of Current Therapeutic Modalities [PDF]

Biomedicines
Hypertrophic cardiomyopathy (HCM) is often associated with left ventricular outflow tract (LVOT) obstruction, which affects a substantial proportion of patients.
Marco Maria Dicorato, Gaetano Citarelli, Francesco Mangini, Rossella Alemanni, Miriam Albanese, Sebastiano Cicco, Cosimo Angelo Greco, Cinzia Forleo, Paolo Basile, Maria Cristina Carella, Marco Matteo Ciccone, Andrea Igoren Guaricci, Ilaria Dentamaro   +12 more
doaj   +2 more sources

Myosin inhibitors for treatment of hypertrophic cardiomyopathy. [PDF]

Cochrane Database Syst Rev
Objectives: This is a protocol for a Cochrane Review (intervention). The objectives are as follows:/ / Primary objective: To assess the effects of myosin inhibitors compared to usual care or placebo on exercise capacity, need for septal reduction ...
Quill S, Amin AS, Asselbergs FW, Bezzina C, Elliott PM, van der Velden J, Schmidt AF.   +6 more
europepmc   +3 more sources

Obstructive hypertrophic cardiomyopathy: from genetic insights to a multimodal therapeutic approach with mavacamten, aficamten, and beyond [PDF]

The Egyptian Heart Journal
Background A cardiac condition marked by excessive growth of heart muscle cells, hypertrophic cardiomyopathy (HCM) is a complex genetic disorder characterized by left ventricular hypertrophy, microvascular ischemia, myocardial fibrosis, and diastolic ...
Khadija Sarwer, Saeeda Lashari, Nida Rafaqat, Maher, Abdul Raheem, Muneeb Ur Rehman, Syed Muhammad Iraj Abbas   +6 more
doaj   +2 more sources